Plasma Concentrations of 8-hydroxy-2'-deoxyguanosine and Risk of Kidney Disease and Death in Individuals with Type 1 Diabetes
Overview
Authors
Affiliations
Aims/hypothesis: Oxidative stress is involved in the pathogenesis of diabetic kidney disease. We evaluated the association between 8-hydroxy-2'-deoxyguanosine (8-OHdG), a marker of DNA oxidative damage, and end-stage renal disease (ESRD) or death in individuals with type 1 diabetes.
Methods: Plasma 8-OHdG concentrations were measured at baseline in participants with type 1 diabetes from GENEDIAB (n = 348) and GENESIS (n = 571) cohorts. A follow-up was conducted in 205 and 499 participants for a mean ± SD duration of 8.9 ± 2.3 years and 5.2 ± 1.9 years, respectively. We tested associations between 8-OHdG concentrations and urinary albumin concentration (UAC) or eGFR at baseline, and the risk of ESRD or all-cause mortality during follow-up. Analyses were performed in pooled cohorts.
Results: The highest UAC (geometric mean [95% CI]) was observed in the third 8-OHdG tertile (tertile 1, 9 [6, 13] mg/l; tertile 2, 10 [7, 16] mg/l; tertile 3, 16 [10, 25] mg/l; p = 0.36 for tertile 1 vs tertile 2 and p = 0.003 for tertile 3 vs tertile 1) after adjustment for potential confounding covariates. The lowest eGFR (mean [95% CI]) was observed in the third tertile (tertile 1, 87 [82, 93] ml min 1.73 m; tertile 2, 88 [82, 94] ml min 1.73 m; tertile 3, 74 [68, 80] ml min 1.73 m; p = 0.61 for tertile 1 vs tertile 2; p < 0.001 for tertile 3 vs tertile 1). ESRD and death occurred in 48 and 64 individuals, respectively. The HR for ESRD, but not death, was higher in the third tertile than in the first (tertile 2 vs tertile 1, 1.45 [0.45, 5.04], p = 0.54; tertile 3 vs tertile 1, 3.05 [1.16, 9.60], p = 0.02) after multiple adjustments.
Conclusions/interpretation: Higher plasma concentrations of 8-OHdG were independently associated with increased risk of kidney disease in individuals with type 1 diabetes, suggesting that this marker can be used to evaluate the progression of diabetic kidney disease.
Perez-Montero B, Fermin-Rodriguez M, Portero-Fuentes M, Sarquis J, Caceres S, Portal J BMC Vet Res. 2025; 21(1):161.
PMID: 40069799 PMC: 11900598. DOI: 10.1186/s12917-025-04614-1.
Jamal A, Brettle H, Jamil D, Tran V, Diep H, Bobik A Biomolecules. 2024; 14(6).
PMID: 38927040 PMC: 11201492. DOI: 10.3390/biom14060637.
AlTamimi J, AlFaris N, Alshammari G, Alagal R, Aljabryn D, Yahya M Saudi Pharm J. 2023; 31(11):101817.
PMID: 37915829 PMC: 10616554. DOI: 10.1016/j.jsps.2023.101817.
Novel Biomarkers of Diabetic Kidney Disease.
Rico-Fontalvo J, Aroca-Martinez G, Daza-Arnedo R, Cabrales J, Rodriguez-Yanez T, Cardona-Blanco M Biomolecules. 2023; 13(4).
PMID: 37189380 PMC: 10135955. DOI: 10.3390/biom13040633.
SH3YL1 Protein Predicts Renal Outcomes in Patients with Type 2 Diabetes.
Han S, Han S, Ghee J, Cha J, Kang Y, Cha D Life (Basel). 2023; 13(4).
PMID: 37109492 PMC: 10141384. DOI: 10.3390/life13040963.